What is the history of Ehlers Danlos?

The history of Ehlers-Danlos syndrome (EDS) dates back to the late 19th and early 20th centuries, when physicians first recognized a cluster of symptoms involving skin hyperextensibility, joint hypermobility, and tissue fragility.

Early Observations and Clinical Characterization

While Hippocrates described individuals with "loose joints" as early as 400 BC, the formal medical recognition of Ehlers-Danlos began in 1891 when Danish dermatologist Edvard Ehlers described a patient with joint laxity and skin fragility. Shortly thereafter, in 1908, French physician Henri-Alexandre Danlos further characterized the condition, leading to the eponym we use today. For decades, the condition was poorly understood, often misdiagnosed as generalized clumsiness or dismissed as minor physical quirks.

Evolution of Understanding and Genetics

The mid-20th century marked a turning point in our understanding of Ehlers-Danlos. As clinical genetics emerged, researchers identified that the condition was not a single entity but a group of heterogeneous disorders. The 1997 Villefranche nosology was a major milestone, categorizing the condition into distinct subtypes based on clinical presentation. Today, the 2017 international classification systems, bolstered by next-generation sequencing, have allowed us to pinpoint specific genetic mutations—such as those in the COL5A1 or COL5A2 genes—that define the classical form of Ehlers-Danlos.

From Misconception to Patient Advocacy

Historically, patients were often stigmatized or told their pain was psychosomatic due to the "invisible" nature of Ehlers-Danlos. Misconceptions that it was purely a "skin condition" have been corrected through decades of patient-led advocacy and the rise of global communities like DiseaseMaps.org. These efforts have moved the focus from merely identifying symptoms to a multidisciplinary approach involving physical therapy, cardiology, and pain management, significantly improving the quality of life for those living with Ehlers-Danlos.

Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: The portal for rare diseases and orphan drugs


• Online Mendelian Inheritance in Man (OMIM)


• The Ehlers-Danlos Society